Vibativ was recently approved by the FDA for the treatment of complicated skin and skin structure infections.
“We are very pleased with the FDA’s approval of VIBATIV, and extremely excited about the prospect of bringing this new medicine to the market,” said Rick E Winningham, Theravance’s Chief Executive Officer. “This is a significant event that marks the first approved indication for VIBATIV and validates Theravance’s strategies in drug discovery and development. We believe that VIBATIV will become an important medicine addressing the urgent medical need for new antibiotics to treat Gram-positive infections caused by MRSA.”
